Procainamide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Procainamide: From Cardiac Arrhythmia to Tourette Syndrome
One-Sentence Summary
Procainamide is classically known as a Class Ia antiarrhythmic (sodium channel blocker) used for cardiac arrhythmias, though the evidence pack itself contains no structured record of its original approved indication. The TxGNN model’s top prediction is Tourette syndrome, but this is supported by 0 clinical trials and 0 publications — the signal comes purely from the model score, with no mechanistic, clinical, or literature evidence behind it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from evidence pack (no license records; drug is generally known as a Class Ia antiarrhythmic) |
| Predicted New Indication | Tourette syndrome |
| TxGNN Prediction Score | 99.46% |
| Evidence Level | L5 |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action (MOA) data for procainamide is not available in this evidence pack (flagged as a High-severity data gap). Based on general pharmacological knowledge, procainamide is a Class Ia antiarrhythmic that acts via cardiac sodium channel blockade, and is not associated with any known central nervous system or neuropsychiatric mechanism.
For the top-ranked prediction, Tourette syndrome, the model’s own repurposing rationale is explicit and cautionary: “no known mechanistic link — procainamide is a sodium channel blocker with no relationship to the dopamine/GABA-related pathology of Tourette syndrome; this is purely a model prediction score with no clinical or literature support.” No clinical trials or published literature currently support this indication.
Given this, the prediction should be treated as an unvalidated model artifact rather than a scientifically grounded repurposing hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No marketing authorizations are on record for procainamide in this evidence pack (total_licenses: 0); market status is listed as Not marketed.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Tourette syndrome) has a high TxGNN similarity score but zero supporting clinical trials, zero publications, and an explicitly stated lack of mechanistic plausibility — this is Evidence Level L5 (model prediction only). The drug is also not currently marketed and lacks basic MOA and safety-label data, both flagged as blocking/high-severity gaps.
Additional context: the other high-ranked candidates in this evidence pack do not strengthen the case — literature for hyperthyroidism and Prinzmetal angina describes procainamide being used to manage arrhythmic complications in those conditions rather than treating the underlying disease, and evidence for rheumatoid arthritis points in the opposite direction (procainamide is a well-documented cause of drug-induced lupus/autoantibody formation, a safety signal rather than a therapeutic one).
To proceed, the following is needed:
- Procainamide MOA data (DrugBank API query)
- TFDA/FDA label warnings, contraindications, and DDI data (currently all [Data Gap])
- A dedicated mechanistic rationale connecting sodium-channel blockade to Tourette syndrome pathophysiology, ideally from preclinical or case-level sources
- Reassessment of lower-ranked candidates only if independent mechanistic evidence emerges — current top candidates do not warrant further investment at this time
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.